Global Follicular Lymphoma Drugs Market Size, Share, Trends and Forecast 2022-2030

Description

Market Analysis and Insights: Global Follicular Lymphoma Drugs Market
Follicular lymphoma is a cancer that affects white blood cells called lymphocytes. There are two types of lymphomas: Hodgkin's and non-Hodgkin's, based on the kind of white blood cell they affect. Follicular lymphoma is a non-Hodgkin's lymphoma.Drugs for Follicular lymphoma are Anti-CD20 mAbs, Chemotherapy Agents, Kinase Inhibitor, etc.

The global Follicular Lymphoma Drugs market size is projected to reach US$ 2836.9 million by 2028, from US$ 1711.1 million in 2021, at a CAGR of 7.4% during 2022-2028.

Global core follicular lymphoma drugs players include Roche, Teva and Bayer etc. The Top3 companies hold a share about 57%. North America is the largest market, with a share about 58%, followed by Europe and Asia Pacific with the share about 21% and 20%.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Follicular Lymphoma Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Follicular Lymphoma Drugs market in terms of revenue.

Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Follicular Lymphoma Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Follicular Lymphoma Drugs market.

Impact of Covid-19 Outbreak

This section of the report has explored the overall status of the Covid scenario and has offered valuable insights into the changes in supply chain disruption, fluctuations in demand, etc. The analysts have also focused on the key measures that the companies are opting to withstand the harsh scenario.

Segmental Analysis

The report has been segmented into product and application segments. The researchers have documented all the products present today in the Follicular Lymphoma Drugs market. They have also shed light on the new product innovations and launches by the key players. In the segmental analysis, the analysts have provided revenue forecast figures based on type and application for the period 2017-2028. They have also discussed about the growth rate and potential of each segment for the period 2017-2028.

Follicular Lymphoma Drugs Breakdown Data by Type

Anti-CD20 mAbs

Chemotherapy Agents

Kinase Inhibitor

Others

Follicular Lymphoma Drugs Breakdown Data by Administration Route

Injection

Oral

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Competitive Landscape

This segment focuses on the key players operating in the industry. It underlines all the current and future activities by the prominent manufacturers. By understanding various initiatives being taken up by different players, readers will gain the ability to settle on correct business choices. The authors of the report have provided accurate revenue figures of the companies for the period 2017-2022. The clients are sure to gain the upper hand once they get hold of this report. Key players studied in the research report include:

Roche

Gilead Sciences

TG Therapeutics

Bayer

Secura Bio

Epizyme

Eisai

Acrotech Biopharma

Teva

Eagle Pharmaceuticals

MundiPharma

TABLE OF CONTENT

1 Report Business Overview
1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Follicular Lymphoma Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028

1.2.2 Anti-CD20 mAbs

1.2.3 Chemotherapy Agents

1.2.4 Kinase Inhibitor

1.2.5 Others

1.3 Market by Administration Route

1.3.1 Global Follicular Lymphoma Drugs Market Size Growth Rate by Administration Route, 2017 VS 2021 VS 2028

1.3.2 Injection

1.3.3 Oral

1.4 Study Objectives

1.5 Years Considered

2 Global Growth Trends

2.1 Global Follicular Lymphoma Drugs Market Perspective (2017-2028)

2.2 Follicular Lymphoma Drugs Growth Trends by Region

2.2.1 Follicular Lymphoma Drugs Market Size by Region: 2017 VS 2021 VS 2028

2.2.2 Follicular Lymphoma Drugs Historic Market Size by Region (2017-2022)

2.2.3 Follicular Lymphoma Drugs Forecasted Market Size by Region (2023-2028)

2.3 Follicular Lymphoma Drugs Market Dynamics

2.3.1 Follicular Lymphoma Drugs Industry Trends

2.3.2 Follicular Lymphoma Drugs Market Drivers

2.3.3 Follicular Lymphoma Drugs Market Challenges

2.3.4 Follicular Lymphoma Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Follicular Lymphoma Drugs Players by Revenue

3.1.1 Global Top Follicular Lymphoma Drugs Players by Revenue (2017-2022)

3.1.2 Global Follicular Lymphoma Drugs Revenue Market Share by Players (2017-2022)

3.2 Global Follicular Lymphoma Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Follicular Lymphoma Drugs Revenue

3.4 Global Follicular Lymphoma Drugs Market Concentration Ratio

3.4.1 Global Follicular Lymphoma Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Follicular Lymphoma Drugs Revenue in 2021

3.5 Follicular Lymphoma Drugs Key Players Head office and Area Served

3.6 Key Players Follicular Lymphoma Drugs Product Solution and Service

3.7 Date of Enter into Follicular Lymphoma Drugs Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Follicular Lymphoma Drugs Breakdown Data by Type

4.1 Global Follicular Lymphoma Drugs Historic Market Size by Type (2017-2022)

4.2 Global Follicular Lymphoma Drugs Forecasted Market Size by Type (2023-2028)

5 Follicular Lymphoma Drugs Breakdown Data by Administration Route

5.1 Global Follicular Lymphoma Drugs Historic Market Size by Administration Route (2017-2022)

5.2 Global Follicular Lymphoma Drugs Forecasted Market Size by Administration Route (2023-2028)

6 North America

6.1 North America Follicular Lymphoma Drugs Market Size (2017-2028)

6.2 North America Follicular Lymphoma Drugs Market Size by Type

6.2.1 North America Follicular Lymphoma Drugs Market Size by Type (2017-2022)

6.2.2 North America Follicular Lymphoma Drugs Market Size by Type (2023-2028)

6.2.3 North America Follicular Lymphoma Drugs Market Share by Type (2017-2028)

6.3 North America Follicular Lymphoma Drugs Market Size by Administration Route

6.3.1 North America Follicular Lymphoma Drugs Market Size by Administration Route (2017-2022)

6.3.2 North America Follicular Lymphoma Drugs Market Size by Administration Route (2023-2028)

6.3.3 North America Follicular Lymphoma Drugs Market Share by Administration Route (2017-2028)

6.4 North America Follicular Lymphoma Drugs Market Size by Country

6.4.1 North America Follicular Lymphoma Drugs Market Size by Country (2017-2022)

6.4.2 North America Follicular Lymphoma Drugs Market Size by Country (2023-2028)

6.4.3 United States

6.4.4 Canada

7 Europe

7.1 Europe Follicular Lymphoma Drugs Market Size (2017-2028)

7.2 Europe Follicular Lymphoma Drugs Market Size by Type

7.2.1 Europe Follicular Lymphoma Drugs Market Size by Type (2017-2022)

7.2.2 Europe Follicular Lymphoma Drugs Market Size by Type (2023-2028)

7.2.3 Europe Follicular Lymphoma Drugs Market Share by Type (2017-2028)

7.3 Europe Follicular Lymphoma Drugs Market Size by Administration Route

7.3.1 Europe Follicular Lymphoma Drugs Market Size by Administration Route (2017-2022)

7.3.2 Europe Follicular Lymphoma Drugs Market Size by Administration Route (2023-2028)

7.3.3 Europe Follicular Lymphoma Drugs Market Share by Administration Route (2017-2028)

7.4 Europe Follicular Lymphoma Drugs Market Size by Country

7.4.1 Europe Follicular Lymphoma Drugs Market Size by Country (2017-2022)

7.4.2 Europe Follicular Lymphoma Drugs Market Size by Country (2023-2028)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Follicular Lymphoma Drugs Market Size (2017-2028)

8.2 Asia-Pacific Follicular Lymphoma Drugs Market Size by Type

8.2.1 Asia-Pacific Follicular Lymphoma Drugs Market Size by Type (2017-2022)

8.2.2 Asia-Pacific Follicular Lymphoma Drugs Market Size by Type (2023-2028)

8.2.3 Asia-Pacific Follicular Lymphoma Drugs Market Share by Type (2017-2028)

8.3 Asia-Pacific Follicular Lymphoma Drugs Market Size by Administration Route

8.3.1 Asia-Pacific Follicular Lymphoma Drugs Market Size by Administration Route (2017-2022)

8.3.2 Asia-Pacific Follicular Lymphoma Drugs Market Size by Administration Route (2023-2028)

8.3.3 Asia-Pacific Follicular Lymphoma Drugs Market Share by Administration Route (2017-2028)

8.4 Asia-Pacific Follicular Lymphoma Drugs Market Size by Region

8.4.1 Asia-Pacific Follicular Lymphoma Drugs Market Size by Region (2017-2022)

8.4.2 Asia-Pacific Follicular Lymphoma Drugs Market Size by Region (2023-2028)

8.4.3 China

8.4.4 Japan

8.4.5 South Korea

8.4.6 Southeast Asia

8.4.7 India

8.4.8 Australia

9 Latin America

9.1 Latin America Follicular Lymphoma Drugs Market Size (2017-2028)

9.2 Latin America Follicular Lymphoma Drugs Market Size by Type

9.2.1 Latin America Follicular Lymphoma Drugs Market Size by Type (2017-2022)

9.2.2 Latin America Follicular Lymphoma Drugs Market Size by Type (2023-2028)

9.2.3 Latin America Follicular Lymphoma Drugs Market Share by Type (2017-2028)

9.3 Latin America Follicular Lymphoma Drugs Market Size by Administration Route

9.3.1 Latin America Follicular Lymphoma Drugs Market Size by Administration Route (2017-2022)

9.3.2 Latin America Follicular Lymphoma Drugs Market Size by Administration Route (2023-2028)

9.3.3 Latin America Follicular Lymphoma Drugs Market Share by Administration Route (2017-2028)

9.4 Latin America Follicular Lymphoma Drugs Market Size by Country

9.4.1 Latin America Follicular Lymphoma Drugs Market Size by Country (2017-2022)

9.4.2 Latin America Follicular Lymphoma Drugs Market Size by Country (2023-2028)

9.4.3 Mexico

9.4.4 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Follicular Lymphoma Drugs Market Size (2017-2028)

10.2 Middle East & Africa Follicular Lymphoma Drugs Market Size by Type

10.2.1 Middle East & Africa Follicular Lymphoma Drugs Market Size by Type (2017-2022)

10.2.2 Middle East & Africa Follicular Lymphoma Drugs Market Size by Type (2023-2028)

10.2.3 Middle East & Africa Follicular Lymphoma Drugs Market Share by Type (2017-2028)

10.3 Middle East & Africa Follicular Lymphoma Drugs Market Size by Administration Route

10.3.1 Middle East & Africa Follicular Lymphoma Drugs Market Size by Administration Route (2017-2022)

10.3.2 Middle East & Africa Follicular Lymphoma Drugs Market Size by Administration Route (2023-2028)

10.3.3 Middle East & Africa Follicular Lymphoma Drugs Market Share by Administration Route (2017-2028)

10.4 Middle East & Africa Follicular Lymphoma Drugs Market Size by Country

10.4.1 Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2017-2022)

10.4.2 Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2023-2028)

10.4.3 Turkey

10.4.4 Saudi Arabia

10.4.5 UAE

11 Key Players Profiles

11.1 Roche

11.1.1 Roche Company Details

11.1.2 Roche Business Overview

11.1.3 Roche Follicular Lymphoma Drugs Introduction

11.1.4 Roche Revenue in Follicular Lymphoma Drugs Business (2017-2022)

11.1.5 Roche Recent Developments

11.2 Gilead Sciences

11.2.1 Gilead Sciences Company Details

11.2.2 Gilead Sciences Business Overview

11.2.3 Gilead Sciences Follicular Lymphoma Drugs Introduction

11.2.4 Gilead Sciences Revenue in Follicular Lymphoma Drugs Business (2017-2022)

11.2.5 Gilead Sciences Recent Developments

11.3 TG Therapeutics

11.3.1 TG Therapeutics Company Details

11.3.2 TG Therapeutics Business Overview

11.3.3 TG Therapeutics Follicular Lymphoma Drugs Introduction

11.3.4 TG Therapeutics Revenue in Follicular Lymphoma Drugs Business (2017-2022)

11.3.5 TG Therapeutics Recent Developments

11.4 Bayer

11.4.1 Bayer Company Details

11.4.2 Bayer Business Overview

11.4.3 Bayer Follicular Lymphoma Drugs Introduction

11.4.4 Bayer Revenue in Follicular Lymphoma Drugs Business (2017-2022)

11.4.5 Bayer Recent Developments

11.5 Secura Bio

11.5.1 Secura Bio Company Details

11.5.2 Secura Bio Business Overview

11.5.3 Secura Bio Follicular Lymphoma Drugs Introduction

11.5.4 Secura Bio Revenue in Follicular Lymphoma Drugs Business (2017-2022)

11.5.5 Secura Bio Recent Developments

11.6 Epizyme

11.6.1 Epizyme Company Details

11.6.2 Epizyme Business Overview

11.6.3 Epizyme Follicular Lymphoma Drugs Introduction

11.6.4 Epizyme Revenue in Follicular Lymphoma Drugs Business (2017-2022)

11.6.5 Epizyme Recent Developments

11.7 Eisai

11.7.1 Eisai Company Details

11.7.2 Eisai Business Overview

11.7.3 Eisai Follicular Lymphoma Drugs Introduction

11.7.4 Eisai Revenue in Follicular Lymphoma Drugs Business (2017-2022)

11.7.5 Eisai Recent Developments

11.8 Acrotech Biopharma

11.8.1 Acrotech Biopharma Company Details

11.8.2 Acrotech Biopharma Business Overview

11.8.3 Acrotech Biopharma Follicular Lymphoma Drugs Introduction

11.8.4 Acrotech Biopharma Revenue in Follicular Lymphoma Drugs Business (2017-2022)

11.8.5 Acrotech Biopharma Recent Developments

11.9 Teva

11.9.1 Teva Company Details

11.9.2 Teva Business Overview

11.9.3 Teva Follicular Lymphoma Drugs Introduction

11.9.4 Teva Revenue in Follicular Lymphoma Drugs Business (2017-2022)

11.9.5 Teva Recent Developments

11.10 Eagle Pharmaceuticals

11.10.1 Eagle Pharmaceuticals Company Details

11.10.2 Eagle Pharmaceuticals Business Overview

11.10.3 Eagle Pharmaceuticals Follicular Lymphoma Drugs Introduction

11.10.4 Eagle Pharmaceuticals Revenue in Follicular Lymphoma Drugs Business (2017-2022)

11.10.5 Eagle Pharmaceuticals Recent Developments

11.11 MundiPharma

11.11.1 MundiPharma Company Details

11.11.2 MundiPharma Business Overview

11.11.3 MundiPharma Follicular Lymphoma Drugs Introduction

11.11.4 MundiPharma Revenue in Follicular Lymphoma Drugs Business (2017-2022)

11.11.5 MundiPharma Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Author Details

13.3 Disclaimer

Delivery Format : EXCEL/Data Pack

Choose License Type

Checkout Inquiry Sample